HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor
Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.
HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor
HRX-0215 proved to be safe and well tolerated in healthy volunteers.
HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors
He follows Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.